NASDAQ:LXEO Lexeo Therapeutics Q1 2025 Earnings Report $3.68 +0.01 (+0.27%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$3.59 -0.09 (-2.45%) As of 04/25/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Lexeo Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.80Beat/MissN/AOne Year Ago EPSN/ALexeo Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALexeo Therapeutics Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time9:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Lexeo Therapeutics Earnings HeadlinesLexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Buy" by AnalystsApril 27 at 2:24 AM | americanbankingnews.comLexeo Therapeutics (NASDAQ:LXEO) versus Finch Therapeutics Group (NASDAQ:FNCH) Head-To-Head SurveyApril 21, 2025 | americanbankingnews.comWho’s really running AmericaMost Americans have never heard his name… He was instrumental in Trump’s victory. He turned J.D. Vance from a Trump-hater into his vice president. He’s one of the driving forces behind the rise of cryptocurrencies, digital commerce, social media, Big Data, cloud computing, and artificial intelligence... In other words, he’s America’s puppet master. April 28, 2025 | Porter & Company (Ad)Analyzing Protara Therapeutics (NASDAQ:TARA) & Lexeo Therapeutics (NASDAQ:LXEO)April 20, 2025 | americanbankingnews.comLexeo Therapeutics announces ‘positive’ Interim Phase 1/2 data for LX2006April 8, 2025 | markets.businessinsider.comLexeo Therapeutics price target lowered to $22 from $25 at ChardanApril 8, 2025 | markets.businessinsider.comSee More Lexeo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lexeo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexeo Therapeutics and other key companies, straight to your email. Email Address About Lexeo TherapeuticsLexeo Therapeutics (NASDAQ:LXEO) operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.View Lexeo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
